✦ LIBER ✦

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib

✍ Scribed by Sofia Jönsson; Therese Standal; Bob Olsson; Dan Mellström; Hans Wadenvik

Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 723 KB
Volume: 87
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.23155

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ocular side effects in chronic myeloid l

Ocular side effects in chronic myeloid leukemia patients treated with imatinib

✍ Massimo Breccia; Fabiana Gentilini; Laura Cannella; Roberto Latagliata; Ida Carm 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 79 KB

Male patients with chronic myeloid leuke

Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: Report of five cases

✍ Massimo Breccia; Laura Cannella; Enrico Montefusco; Annamaria Frustaci; Matteo P 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Long-term prognostic impact of the use o

Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib

✍ Fabio P. S. Santos; Yesid Alvarado; Hagop Kantarjian; Dushyant Verma; Susan O'Br 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 1 views

Occurrence of colon adenocarcinoma in ch

Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: Report of two cases and review of the literature

✍ A. Frustaci; M. Breccia; L. Cannella; C. Stefanizzi; G. Alimena 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Inv (11)(p15q21) in donor-derived Ph-neg

Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stemcell transplantation

✍ Bruno C. Medeiros; Kathy Chun; Suzanne Kamel-Reid; Jeffrey Lipton 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract Imatinib mesylate (IM) is the standard first‐line treatment for patients with chronic myeloid leukemia (CML). Surprisingly, 2–15% of patients achieving a complete cytogenetic response develop cytogenetic abnormalities in Philadelphia (Ph)‐negative cells. Following hematopoietic stem cel